midostaurin (PKC412)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Technische Universität Dresden

Conditions

Acute Myeloid LeukemiaLeukemia

Phase 2

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

CompletedNCT00782067

Novartis PharmaceuticalsLeukemia

Start: 2008-10-13End: 2017-08-24Updated: 2018-11-15

Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML

CompletedNCT01830361

Technische Universität DresdenAcute Myeloid Leukemia

Start: 2013-03-13End: 2019-10-30Updated: 2020-08-06

Related Papers

KIT V560D-Mutated Systemic Mastocytosis Associated With High-Risk Myelodysplastic Syndrome: A Unique Case of Systemic Mastocytosis-Associated Hematologic Neoplasm.

2024-11-302 citations

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.

2020-05-1146 citations

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

New England Journal of Medicine2016-06-29465 citations

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Blood2014-12-0621 citations

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Blood2013-11-1510 citations